Impact of Previous Coronavirus Disease 2019 on Immune Response After a Single Dose of BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine

María Velasco, Maria Isabel Galán, Maria Luisa Casas, Elia Pérez-Fernández, Diana Martínez-Ponce, Beatriz González-Piñeiro, Virgilio Castilla, Carlos Guijarro, Alcorcón COVID-19 Working Group, Alejandro Algora Weber, Juan Carlos Alonso Punter, Gregorio Bonilla Zafra, Mª Mercedes Bueno Campaña, Camilo Carrión Pulido, Ana Isabel Diaz Cuasante, Aurora Fabero Jiménez, Rosa María Fariña García, María Isabel González Anglada, Mª Mercedes Izquierdo Patrón, Susana Lorenzo Martínez, Margarita Mosquera González, Montserrat Pérez Encinas, Elia Pérez Fernandez, Francisco José Pérez Vega, Renilla Sánchez, Maria Esther, Mª José Goyanes Galán, Juan Emilio Losa-García, Gil Rodriguez-Caravaca, María Velasco, Maria Isabel Galán, Maria Luisa Casas, Elia Pérez-Fernández, Diana Martínez-Ponce, Beatriz González-Piñeiro, Virgilio Castilla, Carlos Guijarro, Alcorcón COVID-19 Working Group, Alejandro Algora Weber, Juan Carlos Alonso Punter, Gregorio Bonilla Zafra, Mª Mercedes Bueno Campaña, Camilo Carrión Pulido, Ana Isabel Diaz Cuasante, Aurora Fabero Jiménez, Rosa María Fariña García, María Isabel González Anglada, Mª Mercedes Izquierdo Patrón, Susana Lorenzo Martínez, Margarita Mosquera González, Montserrat Pérez Encinas, Elia Pérez Fernandez, Francisco José Pérez Vega, Renilla Sánchez, Maria Esther, Mª José Goyanes Galán, Juan Emilio Losa-García, Gil Rodriguez-Caravaca

Abstract

Immune response after a single dose of BNT162b2 vaccine was markedly increased in subjects with previous severe acute respiratory syndrome coronavirus 2 infection, reaching similar immunoglobulin titers to those elicited by the full 2 doses in naive cases, and increased modestly after the second dose. These data may inform the priority of the boosting dose.

Keywords: COVID-19; SARS-CoV-2; health care workers; immune response; vaccine.

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Serological response after 1 or 2 doses of the BNT162b2 messenger RNA coronavirus disease 2019 (COVID-19) vaccine in 641 health care workers. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G anti-spike (IgG-S) were determined 3 weeks after the first dose (light blue dots; n = 641) and 3 weeks after the second dose (dark blue dots; n = 623) with chemiluminescent immunoanalysis (Architect, ABBOTT Diagnostics) with a cutoff of U test, and Kruskal-Wallis test were used, as appropriate, to compare IgG-S titers between groups. Multiple comparisons were adjusted by the Bonferroni method. A, IgG-S titers in individuals who were SARS-CoV-2 naive or with previously documented infection. Of note, the strong serologic response in previously infected individuals after the first dose was of similar magnitude to that elicited by the 2-dose vaccine protocol in naive subjects. B, IgG-S titers in individuals according to their serologic SARS-CoV-2 status before vaccination. Seronegative: seronegative in both surveys. Transient seropositivity: seropositive in first survey and negative in second survey. Persistent seropositivity: seropositive in both surveys. Of note, the strong serologic response in infected individuals with persistent seropositivity after the first dose was even higher than that elicited by the 2-dose vaccine protocol in naive and transient seropositive patients (P < .001 for both comparisons); the response to the first dose of the vaccine in transient seropositive subjects was intermediate between seronegative subjects and persistent seropositive subjects. Boost effect was inversely related to the strength of the response to the first dose (P < .001; Supplementary Table 3). C, IgG-S titers in SARS-CoV-2–infected individuals according to their clinical COVID-19 presentation. Of note, the strong serologic response in subjects with previous SARS-CoV-2 infection after the first dose was even higher than that elicited by the 2-dose vaccine protocol in SARS-CoV-2–naive patients and increased progressively with the severity of the disease (P < .001). Boost effect was inversely related to the strength of the response to the first dose (P < .001; Supplementary Table 3).

References

    1. World Health Organization. Background document on the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19: background document to the WHO interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing, 14 January 2021. 2021. Available at: . Accessed 8 May 2021.
    1. Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group . safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383:2603–15.
    1. Manisty C, Otter AD, Treibel TA, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet 2021; 397:1057–8.
    1. Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet 2021; 397:1178–81.
    1. Krammer F, Srivastava K, Alshammary H, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med 2021; 384:1372–4.
    1. Saadat S, Rikhtegaran Tehrani Z, Logue J, et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA 2021; 325:1467–9.
    1. Galán MI, Velasco M, Casas ML, et al. Hospital-wide SARS-CoV-2 seroprevalence in health care workers in a Spanish teaching hospital [manuscript published online ahead of print 18 December 2020]. Enferm Infecc Microbiol Clin 2020. doi:10.1016/j.eimc.2020.11.015.
    1. Bartsch YC, Fischinger S, Siddiqui SM, et al. Discrete SARS-CoV-2 antibody titers track with functional humoral stability. Nat Commun 2021; 12:1018.
    1. Bieniasz P. The case against delaying SARS-CoV-2 mRNA vaccine boosting doses [manuscript published online ahead of print 27 January 2021]. Clin Infect Dis 2021. doi:10.1093/cid/ciab070.
    1. Kadire SR, Wachter RM, Lurie N. Delayed second dose versus standard regimen for Covid-19 vaccination. N Engl J Med 2021; 384:e28.
    1. Vasileiou E, Simpson CR, Robertson C, et al. Effectiveness of first dose of COVID-19 vaccines against hospital admissions in Scotland: national prospective cohort study of 5.4 million people. SSRN [Preprint]. Posted online 19 February 2021. Available at: . Accessed 10 May 2021.
    1. Bubar KM, Reinholt K, Kissler SM, et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science 2021; 371:916–21.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe